Mesa Labs reports Q4 non-GAAP EPS $2.77 vs. $2.20 last year

Reports Q4 revenue $58.90M vs.$55.95M last year. “Several significant strategic milestones were attained in 4Q24 including: closing the acquisition of the GKE China entity on December 31, 2023; extending and expanding our bank credit facility to $200,000 which enabled us to repurchase $75,000, or 43%, of our outstanding 2025 Convertible Notes and ensure that we have the cash available to complete the full repurchase at maturity, if not sooner; executing a restructuring in our Clinical Genomics division to better align our cost structure with the current revenue headwinds; and reducing inventory, excluding the impact of GKE, by 19.4% versus FY23 via our improved procurement processes and the normalization of supply chain delivery times,” said Gary Owens, CEO.